AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~Use of a~~A method of treating a disorder in which aberrant cell division occurs in a human or animal comprising administering to said human or animal a therapeutically effective amount of a peptide comprising the amino acid sequence

$$X_1\ X_2\ X_3\ W\ M\ X_4\ X_5\ X_6\ X_7$$

wherein

the sequence X_1 to X_7 is an amino acid sequence comprising at least 9 amino acids, which may optionally be interrupted by one or two amino acid residues between one or more of the 9 amino acid positions defined herein;

X_1 is selected from W, T, PE, KQI, VV, PQT, H, RI and absent;

X_2 is an amino acid with an aromatic side chain;

X_3 is P or D;

X_4 is an amino acid with a basic side chain;

X_5 is an amino acid with a charged side chain;

X_6 is an amino acid with a charged side chain; and

X_7 is an amino acid with a basic side chain or Serine~~;~~

~~in the manufacture of a medicament for treating or preventing a disorder in which aberrant cell division occurs~~.

2. (Currently amended) ~~Use~~ The method according to claim 1 wherein X_2 is Y, F or W.

3. (Currently amended) The method ~~Use~~ according to claim 1 or 2 wherein X_4 is K, R or H.

4. (Currently amended) The method ~~Use~~ according to ~~any one of the preceding~~ claims 1 wherein X_5 is K, R, E, H, D, N or Q.

5. (Currently amended) ~~Use~~ The method according to ~~any one of the preceding~~ claims 1 wherein X_6 is K, R, E, H, D, N or Q.

6. (Currently amended) ~~Use~~ The method according to ~~any one of the preceding~~ claims 1 wherein X_7 is H, S, R or K.

7. (Currently amended) ~~Use~~ The method according to claim 1 wherein X_2 is F or Y, X_4 is K or R, X_5 is K, R or E, X_6 is H, R, Q or K and X_7 is H, S, R or K.

8. (Currently amended) ~~Use~~ The method according to claim 7 wherein X_2 is Y and X_3 is P.

9. (Currently amended) ~~Use~~ The method according to claim 8 wherein said peptide X_1 to X_7 has the amino acid sequence W Y P W M K K H H R.

10. (Currently amended) ~~Use~~ The method according to ~~any one of the preceding~~ claims 1 wherein said peptide further comprises a cell penetration moiety.

11. (Currently amended) ~~Use~~ The method according to claim 10 wherein said cell penetration moiety is linked directly to the carboxy- terminal of the peptide X_1 to X_7.

12. (Currently amended) ~~Use~~ The method according to claim 10 or 11 wherein said cell penetration moiety has the amino acid sequence:

X_8 Q I K I W F Q N R R M K W K K

wherein X_8 is R or Q.

13 (Currently amended) ~~Use~~ The method according to claim 10 ~~or 11~~ wherein said cell penetration moiety has the amino acid sequence

X_8 Q X_9 X_{10} X_{11} W F Q N X_{12} X_{13} M X_{14} W X_{15} X_{16}

wherein

X_8 is R or Q,

X_9, X_{11} are each independently I or L, and

X_{10}, X_{12}, X_{13}, X_{14}, X_{15} and X_{16} are each independently K or R

14 (Currently amended) ~~Use~~ The method according to claim 10 ~~or 11~~ wherein said cell penetration moiety has the amino acid sequence:

QIRIWFQNRRMKWKK;

QIKIWFQNKRMKWKK;

QIKIWFQNKKMKWKK;

QIRIWFQNRKMKWKK;

QIRIWFQNRRMRWKK;

QIRIWFQNRRMKWRK;

QIRIWFQNRRMKWKR;

QIRIWFQNRRMKWRR;

QIRIWFQNRRMKWKK;

QIKIWFQNRRMKWRK;

QIRIWFQNKRMKWRK;

QIKLWFQNRRMKWKK,

QLKLWFQNRRMKWKK; or

QLRIWFQNRRMKWKK.

15. (Currently amended) ~~Use~~ The method according to claim 10 wherein said peptide has the sequence

W Y P W M K K H H R Q I K I W F Q N R R M K W K, or

W Y P W M K K H H R Q I K I W F Q N R R M K W K K

16. (Currently amended) ~~Use~~ The method according to claim 1 wherein said peptide has the sequence

W Y P W M K K H H R.

17. (Currently amended) ~~Use~~ The method according to ~~any one of the preceding~~ claims wherein said disorder is a cancer.

18. (Currently amended) ~~Use~~ The method according to ~~any one of the preceding~~ claims 1 wherein said cells express one or more Hox genes.

19. (Currently amended) ~~Use~~ The method according to ~~any one of the preceding~~ claims 1 wherein PBX does not act as an oncogene in said cells.

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Currently amended) A method reducing the side effects of a cytotoxic or chemotherapeutic agent, in a human or animal comprising administering to said human or animal ~~Use of a~~the peptide as defined ~~in any one of~~ claims ~~1 to 16 in the manufacture of a medicament for reducing the side effects of a cytotoxic or chemotherapeutic agent~~.

24. (Currently amended) A method of maintaing or expanding a stem cell population *in vivo* in a human or animal comprising administering to said human or animal ~~Use of a~~the

peptide as defined in ~~any one of~~ claims 1 ~~to 16 in the manufacture of a medicament for maintaining or expanding a stem cell population *in vivo*~~.

25. (Canceled)

26. (Currently amended) A method according to claim ~~25~~ 1 wherein said human or animal is also administered a cytotoxic or chemotherapeutic agent.

27. (Currently amended) A method of maintaining or expanding stem cells *ex vivo* comprising contacting said stem cells with ~~a~~ the peptide as defined in ~~any one of~~ claims 1 ~~to 16~~.

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

33. (Canceled)

34. (Currently amended) A pharmaceutical composition comprising a peptide as defined in ~~any one of~~ claims 1 ~~to 16~~ and a pharmaceutically acceptable carrier.

35. (Currently amended) A pharmaceutical composition according to claim ~~32~~ 34 further comprising a cytotoxic or chemotherapeutic agent.